TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+11.86%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$395M
AUM Growth
+$395M
(+37%)
Cap. Flow
+$107M
Cap. Flow
% of AUM
26.97%
Top 10 Holdings %
Top 10 Hldgs %
65.16%
Holding
37
New
10
Increased
12
Reduced
2
Closed
12
Top Buys
| 1 |
Amgen
AMGN
|
$25.7M |
| 2 |
Insmed
INSM
|
$21.2M |
| 3 |
argenx
ARGX
|
$20M |
| 4 |
Pfizer
PFE
|
$16.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$16.4M |
Top Sells
| 1 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$19.9M |
| 2 |
Merck
MRK
|
$15.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$14.9M |
| 4 |
Baxter International
BAX
|
$13.6M |
| 5 |
Tandem Diabetes Care
TNDM
|
$11.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arcturus Therapeutics
ARCT
$467M
| – | – |
-138,927
| Closed | -$4.69M |
|
27
Arcutis Biotherapeutics
ARQT
$1.91B
| – | – |
-449,694
| Closed | -$4.46M |
|
28
Astria Therapeutics
ATXS
$394M
| – | – |
-369,549
| Closed | -$5.2M |
|
29
Exact Sciences
EXAS
$9.33B
| – | – |
-90,000
| Closed | -$6.22M |
|
30
Lyra Therapeutics
LYRA
$11.8M
| – | – |
-978,793
| Closed | -$6.09M |
|
|
31
Merck
MRK
$210B
| – | – |
-119,200
| Closed | -$15.7M |
|
|
SILK
32
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| – | – |
-1,083,605
| Closed | -$19.9M |
|
|
ALPN
33
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| – | – |
-120,687
| Closed | -$4.78M |
|
|
34
Baxter International
BAX
$12.1B
| – | – |
-317,566
| Closed | -$13.6M |
|
35
Perspective Therapeutics
CATX
$251M
| – | – |
-780,303
| Closed | -$929K |
|
|
36
Tandem Diabetes Care
TNDM
$834M
| – | – |
-326,506
| Closed | -$11.6M |
|
|
37
Vertex Pharmaceuticals
VRTX
$102B
| – | – |
-35,598
| Closed | -$14.9M |
|